Meningococcal Disease Vaccine Market Report 2026

The meningococcal disease vaccine market size has grown strongly in recent years. It will grow from $2.59 billion in 2025 to $2.84 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to recurring meningococcal disease outbreaks, high mortality and morbidity rates, government-supported vaccination programs, increased awareness of bacterial meningitis, expansion of pediatric immunization schedules.

The meningococcal disease vaccine market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising global travel and migration, increasing focus on preventive healthcare, expansion of vaccine coverage in emerging economies, growth in adolescent immunization initiatives, advancement in vaccine research and development. Major trends in the forecast period include rising adoption of conjugate and recombinant vaccines, expansion of routine immunization programs, increasing focus on adolescent and adult vaccination, growth in travel-related and outbreak-driven vaccination, higher emphasis on early preventive immunization.

The expansion of government immunization programs is anticipated to support the growth of the meningococcal disease vaccine market in the coming years. Government immunization programs are public health initiatives that provide vaccines at no cost or at reduced prices to protect populations from infectious diseases. These programs are increasing due to a stronger focus on disease prevention and reducing the overall healthcare burden through large-scale vaccination efforts. Government immunization programs contribute to the growth of meningococcal vaccines by improving accessibility, boosting immunization rates, raising public awareness, and lowering disease prevalence. They also stimulate demand by enforcing vaccination requirements and advancing public health objectives. For example, in April 2024, according to the Pan American Health Organization (PAHO), a US-based specialized agency, the 22nd Vaccination Week in the Americas (VWA), themed Engage now to protect your future. GetVax, was launched to enhance vaccination coverage, particularly in underserved regions, by delivering more than 65 million vaccine doses. The initiative emphasized addressing misinformation and improving vaccine access through community involvement and targeted outreach campaigns. As a result, the rising number of government immunization programs is driving the growth of the meningococcal disease vaccine market.

Major companies operating in the meningococcal disease vaccine market are concentrating on the development of advanced products, such as pentavalent meningococcal vaccines, to broaden serogroup coverage, simplify immunization schedules, and enhance disease prevention. A pentavalent meningococcal vaccine is an advanced immunization approach designed to protect against five major serogroups of Neisseria meningitidis in a single dose, minimizing the need for multiple separate vaccinations and improving patient adherence. For example, in October 2023, Pfizer Inc., a U.S.-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) approved PENBRAYA, the first and only vaccine indicated for the prevention of meningococcal disease in individuals aged 10 to 25 years. This novel vaccine integrates components from two existing meningococcal vaccines, Trumenba and Nimenrix, to provide protection against the five most prevalent serogroups (A, B, C, W, and Y) of Neisseria meningitidis responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA marks a major advancement in meningococcal disease prevention by offering the widest serogroup coverage of any meningococcal vaccine currently available in the U.S. and has the potential to streamline vaccination regimens by reducing the overall number of doses needed to achieve full protection.

In September 2023, Biovac, a South Africa-based biopharmaceutical company, entered into a partnership with EuBiologics Co. Ltd. to strengthen Africa’s local vaccine innovation and promote self-reliance. The collaboration focuses on technology transfer and the local production of a pentavalent meningococcal meningitis conjugate vaccine in Africa, aiming to meet urgent public health needs across the meningitis belt while enhancing the continent’s vaccine manufacturing independence. EuBiologics Co., Ltd. is a South Korea-based producer of pentavalent meningococcal conjugate vaccines.

Major companies operating in the meningococcal disease vaccine market are Pfizer Inc, Merck & Co Inc, Sanofi SA, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Biovac Institute, Bio Manguinhos, Finlay Institute of Vaccines, Walvax Biotechnology Co Ltd, CSL Limited, China National Biotec Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Hangzhou Jinjiang Group Co Ltd, Shenzhen Kangtai Biological Products Co Ltd, Panacea Biotec, Biological E Limited, Instituto Butantan, Incepta Pharmaceuticals Ltd, Bio Med Pvt Ltd, Bharat Biotech International Ltd, Zhejiang Tianyuan Bio Pharmaceutical Co Ltd, Beijing Tiantan Biological Products Co Ltd.

North America was the largest region in the meningococcal disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the meningococcal disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the meningococcal disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the meningococcal disease vaccine market by increasing costs associated with imported raw materials, vaccine components, cold-chain equipment, and packaging supplies. The impact is most evident for conjugate and recombinant vaccines, particularly in regions dependent on imported vaccines such as Asia-Pacific, Africa, and Latin America. Higher procurement costs have influenced public vaccination budgets and pricing strategies. However, tariffs have also encouraged local vaccine manufacturing, regional production partnerships, and supply chain diversification, supporting long-term vaccine availability and market stability.

The meningococcal disease vaccine market research report is one of a series of new reports that provides meningococcal disease vaccine market statistics, including meningococcal disease vaccine industry global market size, regional shares, competitors with a meningococcal disease vaccine market share, detailed meningococcal disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal disease vaccine industry. This meningococcal disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The meningococcal disease vaccine is designed to protect against meningococcal disease, a severe bacterial infection caused by the bacterium Neisseria meningitidis. This infection can result in meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (blood infection), both of which can be potentially fatal.

The primary types of meningococcal disease vaccines include conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines boost immunity by attaching bacterial sugars to proteins, providing strong protection against strains A, C, W, and Y, particularly for adolescents and individuals at higher risk. These vaccines are available for different age groups, including infants, children, adults, and older adults, and serve various purposes such as preventive vaccination, post-exposure prophylaxis, travel-related vaccination, and outbreak management. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by a range of end-users, including hospitals, specialty clinics, home care services, and more.

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.